The costs of musculoskeletal disease: Health needs assessment and health economics

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 3, 2003, Pages 529-539

  Lubeck, Deborah P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Costs of illness; Musculoskeletal disease; Quality of life in rheumatology

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; ETANERCEPT; GOLD; INFLIXIMAB; METHOTREXATE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ABSENTEEISM; ACCURACY; AMBULATORY CARE; ARTHRITIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DAILY LIFE ACTIVITY; DEPRESSION; DISABILITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EMOTIONAL DISORDER; EMPLOYER; EMPLOYMENT; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICES RESEARCH; HEALTH STATUS; HOME CARE; HOSPITAL CARE; HUMAN; JOINT PROSTHESIS; LENGTH OF STAY; MANAGED CARE; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PRODUCTIVITY; PSYCHOSOCIAL ENVIRONMENT; QUALITY OF LIFE; REVIEW; SCHOOL; SOCIAL ASPECT; SOCIOECONOMICS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; WORK DISABILITY; ECONOMIC EVALUATION; MEDICAL CARE; PREVALENCE;

EID: 0038715490     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(03)00023-8     Document Type: Review

References (62)

1. Centers for Disease Control and Prevention. Arthritis prevalence and activity limitations - United States, 1990. Morbidity and Mortality Weekly Reports 1994; 43: 433-438.
2. Elders MJ. The increasing impact of arthritis on public health. Journal of Rheumatology 2000; 27: 6-8.
3. Allaire SH, Meenan RF & Anderson JJ. The impact of rheumatoid arthritis on the household work performance of women. Arthritis & Rheumatism 1991; 34: 669-678.
4. Yelin E. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates. Journal of Rheumatology 1996; 23(supplement): 47-51.
5. Yelin EH & Katz PP. Labor force participation among persons with musculoskeletal conditions, 1970-1987: National estimates derived from a series of cross-sections. Arthritis & Rheumatism 1991; 34: 1361-1370.
6. Yelin EH, Trupin LS & Sebesta DS. Transitions in employment, morbidity, and disability among persons ages 51-61 with musculoskeletal and non-musculoskeletal conditions in the US, 1992-94. Arthritis & Rheumatism 1999; 42: 769-779.
7. Pincus T, Mitchell J & Burkhauser R. Substantial work disability and earnings losses in individuals less than 65 with osteoarthritis: Comparisons with rheumatoid arthritis. Journal of Clinical Epidemiology 1989; 42: 449-457.
8. Meenan RF, Callahan FL & Helmick CG. The national arthritis action plan: A public health strategy for a looming epidemic. Arthritis Care Research 1999; 12: 79-81.
9. Yelin EH & Katz PP. Transitions in health status among community-dwelling elderly people with arthritis: A national, longitudinal study. Arthritis & Rheumatism 1990; 33: 1205-1215.
10. Hodgson TA & Meiner MR. Cost of illness methodology: A guide to current practices and procedures. Milbank Memorial Fund Quarterly, Health and Society 1982; 60: 429-462.
11. Rice DP & Cooper BS. The economic value of human life. American Journal of Public Health 1986; 57: 1954-1966.
12. Coyle D, Welch V, Shea B et al. Issues of consensus and debate for economic evaluation in rheumatology. Journal of Rheumatology 2001; 28: 642-647.
13. Felts W & Yelin E. The economic impact of the rheumatic diseases in the United States. Journal of Rheumatology 1989; 16: 867-884.
14. Allare S, Prashker M & Meenan R. The cost of rheumatoid arthritis. Pharmacoeconomics 1994; 6: 513-522.
15. Gabriel SE, Crowson CS, Campion ME et al. Direct medical costs unique to people with arthritis. Journal of Rheumatology 1997; 24: 719-725.
16. Yelin E & Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. Arthritis & Rheumatism 1999; 42: 1209-1218.
17. Fautrel B & Guillemin F. Cost of illness studies in rheumatic diseases. Current Opinion in Rheumatology 2002; 14: 121-126.
18. Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002; 41 (supplement 1): 3-6.
19. Yelin E & Callahan LF. The economic costs and social and psychological impact of musculoskeletal conditions. Arthritis & Rheumatism 1995; 38: 1351-1362.
20. Ward MM, Javitz HS & Yelin EH. The direct cost of rheumatoid arthritis. Value in Health 2000; 3: 243-252.
21. Clarke AE, Zowall H, Levington C et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A 12-year study. Journal of Rheumatology 1997; 24: 1051-1060.
22. Newhall-Perry K, Law NJ, Ramos B et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Journal of Rheumatology 2000; 27: 1156-1163.
23. Cooper NJ, Mugford M, Scott DG et al. Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK. Journal of Rheumatology 2000; 27: 2115-2122.
24. MacLean CH, Knigh K, Paulus H et al. Costs attributable to osteoarthritis. Journal of Rheumatology 1998; 25: 2213-2218.
25. Praemer A, Furner S & Rice DP. Musculoskeletal Conditions in the United States. Park Ridge, IL: American Academy of Orthopaedic Surgeons, 1992.
26. Leigh JP, Seavey W & Leistikow B. Estimating the costs of job related arthritis. Journal of Rheumatology 2001; 28: 1647-1654.
27. Coyte PC, Asche CV, Croxford R & Chan B. The economic cost of musculoskeletal disorders in Canada. Arthritis Care Research 1998; 11: 315-325.
28. Yelin EH, Henke CJ & Epstein WV. Work disability among persons with musculoskeletal conditions. Arthritis & Rheumatism 1986; 29: 1322-1333.
29. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ, and RA-HAQ, DHAQ, and rescored 20-item HAQ (HAQ20): Analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. Journal of Rheumatology 2001; 28: 982-989.
30. Wolfe F & Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. Journal of Rheumatology 1991; 18: 1298-1306.
31. Wolfe F & Pincus T. Standard self-report questionnaire in routine clinical and research practice - An opportunity for patients and rheumatologists (editorial). Journal of Rheumatology 1991; 18: 1298-1306.
32. Suarez-Almazor ME, Conner-Spady B, Kendall CJ et al. Lack of congruence in the ratings of patients' health status by patients and their physicians. Medical Decision Making 2001; 21: 113-121.
33. Wolfe F. Health status questionnaires. Rheumatic Disease Clinics of North America 1995; 21: 990-993.
34. Wolfe F. Practical issues in psychosocial measures. Journal of Rheumatology 1997; 24: 990-993.
35. Long AF & Scott DL. Measuring health status and outcomes in rheumatoid arthritis within routine clinical practice. British Journal of Rheumatology 1994; 33: 682-685.
36. Hawley DJ & Wolfe F. Sensitivity to change of the Health Assessment Questionnaire and other clinical and health status measures in rheumatoid arthritis: Results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Research 1992; 5: 130-136.
37. Lubeck DP. Health-related quality of life measurements and studies in rheumatoid arthritis. American Journal of Management Care 2002; 8: 811-820.
38. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis & Rheumatism 1993; 36: 729-740.
39. Pincus T, Callahan LF, Brooks RH et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Annals of Internal Medicine 1989; 110: 259-266.
40. Radanov BP, Schwarz HA, Frost S-A & Augustiny KF. Relationship between self-rated functional status and psychosocial stress in patients suffering from rheumatoid arthritis. Psychotherapy Psychosomatics 1997; 66: 252-257.
41. Hakala M, Nieminen P & Manelius J. Joint impairment is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population-based series. Journal of Rheumatology 1994; 21: 64-69.
42. Wolfe F & Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. Journal of Rheumatology 1998; 25: 2108-2117.
43. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Annals of Internal Medicine 1999; 130: 478-486.
44. Munro R, Hampson R, McEntegart A et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a five year prospective study. Annals of the Rheumatic Diseases 1998; 57: 88-93.
45. Maini R, St. Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor αmonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet 1999; 354: 1932-1939.
46. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000; 343: 1586-1593.
47. Creed F, Murphy S & Jayson MV. Measurement of psychiatric disorder in rheumatoid arthritis. Journal of Psychosomatic Research 1990; 34: 79-87.
48. Callahan LF, Kaplan MR & Pincus T. The Beck Depression Inventory, Center for Epidemiological Studies Depression Scale (CES-D) and general Well-being Depression Subscale in rheumatoid arthritis. Arthritis Care Research 1991; 4: 3-11.
49. MacKinnon JR, Avison WR & McCain GA. Pain and functional limitations in individuals with rheumatoid arthritis. International Journal of Rehabilitation Research 1994; 17: 49-59.
50. Wolfe F. Fibromyalgia. Rheumatoid Disease Clinics of North America 1990; 16: 681-698.
51. Katz PP & Yelin EH. Activity loss and the onset of depressive symptoms. Do some activities matter more than others. Arthritis & Rheumatism 2001; 44: 1194-1202.
52. Crotty M, McFarlane AC, Brooks PM et al. The psychosocial and clinical status of younger women with early rheumatoid arthritis: A longitudinal study with frequent measures. British Journal of Rheumatology 1994; 33: 754-760.
53. Ware Jr. JE & Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Medical Care 1992; 30: 473-483.
54. Talamo J, Frater A, Gallivan S & Young A. Use of the short form 36 (SF-36) for health status measurement in rheumatoid arthritis. British Journal of Rheumatology 1997; 36: 463-469.
55. Birrell FN, Hassell AB, Jones PW & Dawes PT. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clinical Rheumatology 2000; 19: 195-199.
56. Lubeck DP, Katz P, Yelin E et al. Fatigue in persons with early stage and long term rheumatoid arthritis: Data from RAPOLO. Arthritis & Rheumatism 2002; 46(supplement): S242-S257.
57. Singh A, Wanke LA, Parasuraman TV & Lubeck DP. Reliability and validity of the SF-36 Vitality Scale in measuring vitality of methotrexate-naïve patients with early, active rheumatoid arthritis. Arthritis & Rheumatism 2002; 46(supplement): S115. Abstract 210.
58. Van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP et al. Direct cost of rheumatoid arthritis during the first six years: A cost-of-illness study. British Journal of Rheumatology 1998; 37: 837-847.
59. Clarke AE, Levinton C, Joseph L et al. Predicting the short-term direct medical costs incurred by patients with rheumatoid arthritis. Journal of Rheumatology 1999; 26: 1068-1075.
60. Kobelt G, Eberhardt K, Jonsson L & Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis & Rheumatism 1999; 42: 347-356.
61. Mazzuca SA, Brandt DK, Katz BE et al. Therapeutic strategies distinguish community-based primary care physicians from rheumatologists in the management of osteoarthritis. Journal of Rheumatology 1993; 20: 80-86.
62. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis & Rheumatism 1996; 39: 713-722.